Skip to content

Non-Invasive, Highly Specific Detection of Oxytocin in Biological Fluids

Non-Invasive, Highly Specific Detection of Oxytocin in Biological Fluids

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03140709
Enrollment
28
Registered
2017-05-04
Start date
2016-05-31
Completion date
2016-07-31
Last updated
2017-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oxytocin, Pregnancy

Keywords

Salivary, Oxytocin, Induction, Labor

Brief summary

This study will aid in the development of a research instrument for rapid and highly sensitive detection of perinatal salivary oxytocin, by non-invasive means. There will be two study cohorts: Induction of labor cohort (20) and Cesarean delivery cohort (5) for a total of 25 participants.The standard clinical protocols for administering oxytocin to human subjects at Lucile Packard Children's Hospital will be followed. Oxytocin will be prescribed and dosed as per standard of care with no change due to study enrollment. The study will only involve sampling of saliva and blood. The general hypothesis to be tested is that 1) the sensor will accurately report the levels of oxytocin in saliva samples as compared with standard reference methods and 2) the sensor yields rapid (\<20 minutes) oxytocin results with minimal discomfort to subjects. Overall, this will allow to optimize the administration of oxytocin, and for a better understanding of the blood concentration and effects of oxytocin on mother and child.

Detailed description

Oxytocin, a neuropeptide hormone, plays an important role in the dynamic function of the brain and a variety of complex social behaviors including affiliation, sexual behavior, social recognition, and aggression. Oxytocin is best known for its role to facilitate the birth process through induction of uterine smooth muscle contractions. Oxytocin is primarily used to induce labor, and contract the uterus after delivery. Oxytocin is considered the first line uterotonic to prevent and treat uterine atony and manage postpartum hemorrhage. Currently, there is no instrument that is capable of point-of-care oxytocin detection. A practical research tool to monitor peripheral levels of both endogenous and exogenous oxytocin is therefore needed to better understanding the pharmacokinetics and pharmacodynamics of oxytocin in the mother, fetus and newborn. A better understanding of drug concentration and effect may lead to optimal dosing and better management of induction of labor and/or uterine atony after delivery. With increased research on the importance of oxytocin monitoring, a bedside oxytocin monitor is envisioned that would allow healthcare professionals to improve our pharmacokinetic/dynamic understanding of oxytocin and to monitor and adjust the dose of oxytocin administered during childbirth. Currently, there is no instrument that is capable of point-of-care oxytocin detection.

Interventions

DRUGOxytocin

Induction-Vaginal Delivery: Begin at 1mU/min IV infusion and increase by 2mU/30min q30min to a max of 30mU/min. Postpartum infusion adjusted to 2U/hr. Cesarian Delivery: 1U bolus via IV at delivery, followed by 7.5U/hr up to 30U/hour max depending on uterine tone. Postpartum infusion adjusted to 2U/hr

Sponsors

Giner, Inc
CollaboratorOTHER
Aptagen, LLC
CollaboratorUNKNOWN
Fraunhofer Center for Manufacturing Innovation
CollaboratorUNKNOWN
Rose Biotech, LLC
CollaboratorUNKNOWN
Stanford University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

* Generally healthy, pregnant woman (37-41 weeks) * Scheduled for induction of labor (not already in active labor) or cesarean section * Ages 18-45 years old * ASA physical status 1 or 2 * Singleton pregnancy * Able and willing to sign consent

Exclusion criteria

* Women with any significant medical or obstetric condition (such as gestational hypertension, diabetes,coagulopathy, and renal impairment) * Morbid obesity (BMI greater than/equal to 40) * In active labor upon arrival to L&D

Design outcomes

Primary

MeasureTime frameDescription
Quantification of salivary oxytocin assay levels15 minutes after dose changeTest novel aptamer-based electrochemical assay for the detection and quantification of salivary oxytocin

Secondary

MeasureTime frameDescription
Quantification of blood oxytocin levels15 minutes after dose changeStandard of care detection protocol for oxytocin blood levels to compare sensitivity and specificity of aptamer-based electrochemical assay

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026